Search research articles
Contact Us
Filters
Showing results (431-440 of 490) with videos related to
Page
of 49
Sort By:
Neurology
|
February 27, 2015
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Agnieszka Korfel, Eckhard Thiel, Peter Martus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2010
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma
Andreas Josting, Horst Müller, Peter Borchmann, et al.
Blood
|
September 4, 2004
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
Thomas Kindler, Frank Breitenbuecher, Stefan Kasper, et al.
European Journal of Haematology
|
July 16, 2021
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma
Christian Straka, Hans Salwender, Stefan Knop, et al.
Scientific Reports
|
May 22, 2021
Point-of-care lung ultrasound in COVID-19 patients: inter- and intra-observer agreement in a prospective observational study
Markus H Lerchbaumer, Jonathan H Lauryn, Ulrike Bachmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3
Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
Haematologica
|
March 18, 2014
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
Denise Wolleschak, Thomas S Mack, Florian Perner, et al.
Blood
|
October 13, 2007
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment
Andreas Hochhaus, Brian Druker, Charles Sawyers, et al.
Frontiers in Cell and Developmental Biology
|
March 19, 2021
Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease
Oliver Hartmann, Michaela Reissland, Carina R Maier, et al.
European Journal of Haematology
|
June 25, 2019
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials
Christian Straka, Stefan Knop, Martin Vogel, et al.
Page
of 49
Search research articles
Search
Showing results (431-440 of 490) with videos related to
Sort By:
Page
of 49
Neurology
|
February 27, 2015
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Agnieszka Korfel, Eckhard Thiel, Peter Martus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2010
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma
Andreas Josting, Horst Müller, Peter Borchmann, et al.
Blood
|
September 4, 2004
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
Thomas Kindler, Frank Breitenbuecher, Stefan Kasper, et al.
European Journal of Haematology
|
July 16, 2021
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma
Christian Straka, Hans Salwender, Stefan Knop, et al.
Scientific Reports
|
May 22, 2021
Point-of-care lung ultrasound in COVID-19 patients: inter- and intra-observer agreement in a prospective observational study
Markus H Lerchbaumer, Jonathan H Lauryn, Ulrike Bachmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3
Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
Haematologica
|
March 18, 2014
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
Denise Wolleschak, Thomas S Mack, Florian Perner, et al.
Blood
|
October 13, 2007
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment
Andreas Hochhaus, Brian Druker, Charles Sawyers, et al.
Frontiers in Cell and Developmental Biology
|
March 19, 2021
Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease
Oliver Hartmann, Michaela Reissland, Carina R Maier, et al.
European Journal of Haematology
|
June 25, 2019
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials
Christian Straka, Stefan Knop, Martin Vogel, et al.
Page
of 49